UroGen Pharma (URGN) Cash & Current Investments (2016 - 2026)

UroGen Pharma (URGN) has reported Cash & Current Investments for 11 consecutive years, with $140.3 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Current Investments fell 28.39% year-over-year to $140.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.3 million (down 28.39% YoY) and the FY2025 annual result came in at $120.5 million, down 49.11% from the prior year.
• Cash & Current Investments advanced to $140.3 million in Q1 2026 per URGN's latest filing, from $120.5 million in the prior quarter.
• Over the last five years, Cash & Current Investments for URGN reached as high as $249.6 million in Q3 2024 and fell as low as $47.3 million in Q2 2023.
• A 5-year average of $143.4 million and a median of $137.0 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2023 — Cash & Current Investments sank 52.32% — and 2024, when it jumped 409.67%.
• Year by year, Cash & Current Investments stood at $100.0 million in 2022, then surged by 37.02% to $137.0 million in 2023, then jumped by 72.8% to $236.7 million in 2024, then slumped by 49.11% to $120.5 million in 2025, then increased by 16.45% to $140.3 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $140.3 million, $120.5 million, and $127.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.